Phase I trial of GRC 17536.

Trial Profile

Phase I trial of GRC 17536.

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2011

At a glance

  • Drugs GRC 17536 (Primary)
  • Indications Pain; Respiratory tract disorders
  • Focus Adverse reactions
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 17 Feb 2011 Glenmark reports that the trial is expected to be initiated in the Netherlands in the near future.
    • 17 Feb 2011 Planned End Date is 1 Dec 2011.
    • 30 Aug 2010 Glenmark plans to file the Phase 1 application in January 2011, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top